PHASIFY™ MAX cfDNA extraction kit, powered by novel PHASIFY™ technology, demonstrated 3-fold greater yields of circulating cell-free DNA (cfDNA) and circulating cell-free tumor DNA (ctDNA) in cancer patient plasma compared to the Qiagen QIAamp Circulating Nucleic Acid kit.

I. Improved yield of total DNA (cfDNA)

Figure 1 - The cfDNA was extracted from 89 tissue positive cancer patient plasma samples (1mL) using PHASIFY™ MAX and the QIAamp CNA kit. Total DNA recovery was measured using Quant-iT™ PicoGreen™ dsDNA Assay Kit. On average PHASIFY™ MAX demonstrated a 3.8-fold increase in total DNA recovery compared to QIAamp CNA (P-Value <0.0001 Wilcoxon Signed-Rank). Note, 2 outliers were excluded in which PHASIFY™ MAX generated 209-fold and 800-fold greater recovery.

Figure 1 - The cfDNA was extracted from 89 tissue positive cancer patient plasma samples (1mL) using PHASIFY™ MAX and the QIAamp CNA kit. Total DNA recovery was measured using Quant-iT™ PicoGreen™ dsDNA Assay Kit. On average PHASIFY™ MAX demonstrated a 3.8-fold increase in total DNA recovery compared to QIAamp CNA (P-Value <0.0001 Wilcoxon Signed-Rank). Note, 2 outliers were excluded in which PHASIFY™ MAX generated 209-fold and 800-fold greater recovery.

III. Greater recovery of desired cfDNA fragments

Figure 3 - DNA was extracted from 1 mL healthy human plasma using PHASIFY™ MAX or the QIAamp Circulating Nucleic Acid kit. The extracted DNA were analyzed on Agilent Bioanalyzer 2100, where 35bp and 10,380bp peaks correspond to internal markers.